|Bid||1.1200 x 2900|
|Ask||1.1800 x 1800|
|Day's Range||1.1165 - 1.1900|
|52 Week Range||1.1100 - 7.9700|
|Beta (3Y Monthly)||1.63|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
The Dublin-based company said it had a loss of $1.72 per share. The specialty pharmaceutical company posted revenue of $20.9 million in the period. For the year, the company reported a loss of $95.3 million, ...
DUBLIN, Ireland, March 15, 2019 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced its financial results.
Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Friday, March 15, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2018. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. Avadel Pharmaceuticals plc (AVDL) is a branded specialty pharmaceutical company. Our primarily focus is on the development and potential FDA approval for FT218 which is in a Phase III clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
Avadel Pharmaceuticals plc (AVDL) provided clarification regarding the restructuring actions announced earlier today. The restructuring actions do not trigger a default or violate covenants related to the 4.50% Exchangeable Senior Notes due in 2023.
Avadel Specialty, which sells the company’s Noctiva, the first FDA-approved drug to treat the overproduction of urine at night, plans to sell off its assets and wind down its business, according to a declaration filed Wednesday in U.S. Bankruptcy Court. Avadel expects to record in the fourth quarter of 2018 a pretax noncash impairment charge of $66 million related to Noctiva intangible assets. The move is part of a broader corporate restructuring that calls for Avadel to focus on maximizing the value of FT218, currently in Phase III development for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy.
Avadel Pharmaceuticals plc (AVDL), today announced a corporate restructuring to assure the financial health required to maximize the value of FT218, currently in Phase III development for the treatment of excessive daytime sleepiness (EDS) and Cataplexy in patients suffering from Narcolepsy. Avadel expects to realize $70 to $75 million in cost reductions in 2019 as compared to 2018 as a result of the restructuring plan, driven primarily by exiting NOCTIVA™. “It is clear that FT218, an investigational, once-nightly formulation of sodium oxybate, is the Company’s most promising and commercially-attractive asset targeting a large orphan market with an estimated value of nearly $1.5 billion in 2018,” said Greg Divis, interim Chief Executive Officer of Avadel.
WASHINGTON, Jan. 23, 2019 -- A new awareness campaign called ‘Sleep Normal’ launched Monday to raise awareness of nocturia, an underdiagnosed, treatable, medical condition that.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
- Michael S. Anderson resigns as Chief Executive Officer and member of Avadel’s Board of Directors – - Gregory J. Divis, current Avadel Chief Operating Officer, named Interim.
Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.
Avadel Pharmaceuticals plc (AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that Kevin Kotler, the founder and Portfolio Manager of Broadfin Capital, LLC, has been appointed to the Company’s Board of Directors and will immediately join the Board. The Company also intends to nominate and appoint an additional director, in consultation with Broadfin, in the very near future.
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
WASHINGTON, Nov. 29, 2018 -- Nov. 25-30 acknowledges Nocturia Awareness Week, part of Bladder Health Month, which encourages people to take control of their urinary health..
The Dublin-based company said it had a loss of 43 cents per share. The specialty pharmaceutical company posted revenue of $19.8 million in the period. Avadel expects full-year revenue in the range of $90 ...
DUBLIN, Ireland, Nov. 05, 2018 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system,.
The firm founded Charles Brandes (Trades, Portfolio), Brandes Investment Partners, on Thursday announced that it expanded its position in Avadel Pharmaceuticals Plc (AVDL) to 13.5% of the company, enlarging its exposure to health care, the second-largest sector represented in its portfolio. Warning! GuruFocus has detected 8 Warning Signs with PFE. The value investing firm has been building its stake in Avadel as the company's stock price has declined.